Acurx Pharmaceuticals (ACXP) Q2 2026 Earnings Report

The call conveyed meaningful regulatory, scientific and IP progress (FDA engagement on a potential single pivotal Phase III pathway, trademark allowance for Syfbezi, fully funded PATHFINDER, manufacturing readiness, partnerships, and strengthened cash vs year-end) while also highlighting material challenges: the need to secure substantial funding to run a large international Phase III (ASPIRE), a limited stated runway (~1 year), rising R&D costs tied to trial startup, ongoing operating losses, and potential dilution from financings. On balance the call emphasized significant program and regulatory momentum but also clear near-term financing and execution risks.

On the call Acurx provided detailed clinical and financial guidance: the PATHFINDER 20‑patient open‑label recurrent CDI trial is fully funded, start‑up is underway and enrollment is expected to begin in Q4 2026 (anticipated enrollment ~1–1.5 years), while the single international Phase III ASPIRE pivotal trial is planned but contingent on additional public/private funding; FDA indicated it will consider the totality of evidence (PATHFINDER + ASPIRE and other trials) at a pre‑NDA meeting, acknowledged an 8‑week post‑treatment assessment and accepted a non‑inferiority approach versus vancomycin with a typical 10% lower‑bound margin, and PATHFINDER data could enable LPAD filing for recurrent CDI; financially the company had $10.7M cash at June 30, 2026 (up from $7.6M at Dec 31, 2025), raised approximately $2.5M gross in the quarter via a Registered Direct Offering plus $0.8M from the Equity Line, had earlier arranged up to $7.1M via a registered direct of 825,085 shares at $3.03 and concurrent short‑term warrants for up to 1.65M shares at $2.78 (24‑month expiry), and noted cash/resources (including remaining Equity Line availability) to fund PATHFINDER and operations for at least one year; Q2 R&D was $1.1M vs $0.5M LY (+$0.6M), 6‑month R&D $1.4M vs $1.1M LY (+$0.3M); Q2 G&A $1.2M vs $1.7M LY (‑$0.5M), 6‑month G&A $2.6M vs $3.3M LY (‑$0.7M); net loss Q2 $2.3M or $0.53/diluted share (vs $2.2M or $1.89 LY) and 6‑month net loss $3.9M or $1.13/diluted share (vs $4.4M or $4.01 LY); shares outstanding were 4,683,253 as of June 30, 2026, and the company holds 6 U.S. and 10 international patents, received USPTO trademark allowance and FDA conditional acceptance for the brand name Syfbezi, and retains QIDP/Fast Track designations.